Want to see TSE:ARCH full AI Analyst Report?
Top Page
Arch Biopartners
(ARCH)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.83
▼(-19.90% Downside)
Action:Reiterated
Date:10/21/26
The score is primarily held down by weak financial performance (no TTM revenue, persistent losses and cash burn, and negative equity indicating elevated funding risk). Technical indicators are broadly neutral and do not offset the fundamental weakness, while valuation remains unattractive/unclear due to negative earnings and no dividend support.
Positive Factors
Focused Therapeutic Pipeline
A focused pipeline addressing acute organ and tissue injury gives Arch Biopartners a clearly defined therapeutic mission and development strategy. Concentrating resources on inflammation and ischemia-reperfusion biology may support specialized expertise and a coherent path toward clinical validation.
Negative Factors
No Revenue and Persistent Losses
The absence of current revenue and repeated annual losses show that Arch Biopartners has not yet established a commercial earnings base. This leaves financial performance dependent on future clinical progress and makes sustained profitability uncertain over the coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused Therapeutic Pipeline
A focused pipeline addressing acute organ and tissue injury gives Arch Biopartners a clearly defined therapeutic mission and development strategy. Concentrating resources on inflammation and ischemia-reperfusion biology may support specialized expertise and a coherent path toward clinical validation.
Read all positive factors
Arch Biopartners (ARCH) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$59.10M
Dividend YieldN/A
Average Volume (3M)35.69K
Price to Earnings (P/E)―
Beta (1Y)1.21
Revenue GrowthN/A
EPS Growth-15.53%
CountryCA
Employees6
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding67,933,290
10 Day Avg. Volume32,042
30 Day Avg. Volume35,686
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)-21.63
Price to Sales (P/S)0.00
P/FCF Ratio-53.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)N/A
Arch Biopartners Business Overview & Revenue Model
Company Description
Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to addr...
Arch Biopartners Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 2.12M | 1.98M | 964.68K | 3.89M |
| Gross Profit | 0.00 | 0.00 | -1.66M | -129.00K | -503.00K | -150.00K |
| EBITDA | -2.58M | -1.29M | -75.40K | -335.99K | -101.90K | -76.62K |
| Net Income | -2.83M | -1.55M | -3.92M | -3.33M | -1.41M | -1.17M |
Balance Sheet | ||||||
| Total Assets | 57.22K | 104.53K | 935.62K | 1.17M | 621.64K | 2.67M |
| Cash, Cash Equivalents and Short-Term Investments | 2.91K | 2.10K | 2.97K | 831.27K | 506.35K | 448.24K |
| Total Debt | 2.73M | 2.84M | 2.77M | 5.02M | 4.41M | 5.16M |
| Total Liabilities | 4.04M | 3.99M | 5.28M | 6.68M | 5.09M | 6.55M |
| Stockholders Equity | -3.99M | -3.88M | -4.35M | -5.51M | -4.47M | -3.88M |
Cash Flow | ||||||
| Free Cash Flow | -1.72M | -1.58M | -2.33M | -234.08K | -1.08M | -2.98M |
| Operating Cash Flow | -1.72M | -1.58M | -2.33M | -234.07K | -1.08M | -2.98M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 1.55M | 1.58M | 1.50M | 559.00K | -421.37K | 2.78M |
Arch Biopartners Technical Analysis
Negative
1.03
Price Trends
0.92
Negative
0.87
Negative
0.79
Positive
Market Momentum
-0.01
Negative
43.96
Neutral
70.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ARCH, the sentiment is Negative. The current price of 1.03 is above the 20-day moving average (MA) of 0.85, above the 50-day MA of 0.92, and above the 200-day MA of 0.79, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 43.96 is Neutral, neither overbought nor oversold. The STOCH value of 70.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ARCH.
Arch Biopartners Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | C$43.59M | -0.29 | -147.92% | ― | ― | 85.31% | |
44 Neutral | C$59.10M | -20.47 | 74.79% | ― | ― | -15.53% | |
44 Neutral | C$33.38M | -1.95 | -360.29% | ― | ― | -33.27% | |
42 Neutral | C$205.16M | -3.48 | -72.67% | ― | ― | -6.00% |
* General Sector Average
TSE:ARCH
Arch Biopartners
0.87
-0.11
-11.22%
TSE:MSCL
Satellos Bioscience
9.67
0.43
4.65%
TSE:MDNA
Medicenna Therapeutics Corp
0.43
-0.97
-69.29%
TSE:BCT
BriaCell Therapeutics
5.01
-12.39
-71.21%
TSE:METX
ME Therapeutics Holdings, Inc.
1.06
-3.94
-78.80%
TSE:ONCO
Onco-Innovations Ltd.
1.47
0.00
0.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.